T cell receptors that bind to ny-eso-1 and methods of use thereof
AssigneeMiNK Therapeutics, Inc.
InventorsMarc van Dijk, Volker Seibert, Cornelia Anne Mundt, Arthur Andrew Hurwitz, Mark Adrian Exley, Benjamin Jacob Wolf, Daniel Leventhal, Sébastien Lalevée, Reed Masakayan
Life of this patent
Estimating the term…
Abstract
Provided are TCRs (e.g., TCRs that bind to NY-ESO-1), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.
Claims20
1-147. (canceled)
A method of treating cancer in a subject, the method comprising administering to the subject an effective amount of an engineered cell expressing a T cell receptor (TCR), wherein the TCR comprises an α chain variable region (Vα) comprising complementarity determining regions CDR1α, CDR2α, and CDR3α, and a β chain variable region (Vβ) comprising CDR1β, CDR2β, and CDR3β, wherein the CDR1α, CDR2α, CDR3α, CDR1β, CDR2β, and CDR3β comprise the amino acid sequences set forth in SEQ ID NOs:
- 5, 6, 7, 8, 9, and 10;
- 5, 6, 39, 8, 9, and 10;
- 5, 6, 40, 8, 9, and 10;
- 5, 6, 41, 8, 9, and 10;
- 5, 6, 42, 8, 9, and 10;
- 5, 6, 43, 8, 9, and 10;
- 5, 6, 44, 8, 9, and 10;
- 5, 6, 45, 8, 9, and 10;
- 5, 6, 46, 8, 9, and 10;
- 5, 6, 47, 8, 9, and 10;
- 5, 6, 48, 8, 9, and 10;
- 5, 6, 49, 8, 9, and 10;
- 5, 6, 50, 8, 9, and 10;
- 5, 6, 51, 8, 9, and 10;
- 5, 6, 52, 8, 9, and 10;
- 5, 6, 53, 8, 9, and 10;
- 5, 6, 54, 8, 9, and 10;
- 5, 6, 55, 8, 9, and 10;
- 5, 6, 56, 8, 9, and 10;
- 5, 6, 57, 8, 9, and 10;
- 5, 6, 58, 8, 9, and 10;
- 5, 6, 59, 8, 9, and 10;
- or 5, 6, 60, 8, 9, and 10, respectively.
Dependencies are inferred from the claim text.